|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400088984 |
|
最近更新日期: Date of Last Refreshed on: |
2024-08-29 17:54:03 |
|
注册时间: Date of Registration: |
2024-08-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
回授法联合家庭参与式健康教育对医院-家庭过渡期老年慢性病患者用药安全的影响研究 |
|
Public title: |
Influence of teach-back and family participatory health education on medication safety of older adults with chronic diseases during the transition period from hospital to home |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
回授法联合家庭参与式健康教育对医院-家庭过渡期老年慢性病患者用药安全的影响研究 |
|
Scientific title: |
Influence of teach-back and family participatory health education on medication safety of older adults with chronic diseases during the transition period from hospital to home |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨雨婷 |
研究负责人: |
杨雨婷 |
|
Applicant: |
Yang Yuting |
Study leader: |
Yang Yuting |
|
申请注册联系人电话: Applicant telephone: |
+86 187 5072 2761 |
研究负责人电话:
Study leader's |
+86 187 5072 2761 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
18750722761@163.com |
研究负责人电子邮件: Study leader's E-mail: |
18750722761@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省福州市茶中路20号 |
研究负责人通讯地址: |
福建省福州市茶中路20号 |
|
Applicant address: |
No.20, ChaZhong Road, Fuzhou, Fujian Province, P.R.China |
Study leader's address: |
No.20, ChaZhong Road, Fuzhou, Fujian Province, P.R.China |
|
申请注册联系人邮政编码: Applicant postcode: |
350005 |
研究负责人邮政编码: Study leader's postcode: |
350005 |
|
申请人所在单位: |
福建医科大学附属第一医院 |
||
|
Applicant's institution: |
First Affiliated Hospital of Fujian Medical University |
||
|
研究负责人所在单位: |
福建医科大学附属第一医院 |
||
|
Affiliation of the Leader: |
First Affiliated Hospital of Fujian Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
闽医大附一伦理医研[2024]648号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
福建医科大学附属第一医院医学伦理委员会医学研究与临床技术应用分会 |
||
|
Name of the ethic committee: |
Branch for Medical Research and Clinical Technology Application, Ethics Committee of the First Affiliated Hospital of Fujian Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-08-28 00:00:00 | ||
|
伦理委员会联系人: |
张秀秀 |
||
|
Contact Name of the ethic committee: |
Zhang Xiuxiu |
||
|
伦理委员会联系地址: |
福建省福州市茶中路20号 |
||
|
Contact Address of the ethic committee: |
No.20, ChaZhong Road, Fuzhou, Fujian Province, P.R.China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 591 8798 1029 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
福建医科大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
First Affiliated Hospital of Fujian Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省福州市茶中路20号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.20, ChaZhong Road, Fuzhou, Fujian Province, P.R.China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
福建医科大学启航基金项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Startup Fund for scientific research, Fujian Medical University |
||||||||||||||||||||||
|
研究疾病: |
慢性病 |
||||||||||||||||||||||
|
Target disease: |
Chronic disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
(1)采用量性与质性相结合的方式,探讨老年慢性病患者用药安全知信行影响因素及其相互作用机制。(2)将前期构建的回授法联合家庭参与式健康教育干预方案,经专家会议法修订后,应用于老年慢性病患者,以确定该方案对其用药安全知信行、用药自我管理能力、服药自我效能以及服药依从性的效果。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) To explore the influencing factors and interaction mechanism of drug safety knowledge and practice in elderly patients with chronic diseases by combining quantitative and qualitative methods. (2) The feedback method built earlier combined with family participatory health education intervention plan was applied to elderly patients with chronic diseases after the revision of the expert meeting method, so as to determine the effect of this plan on their medication safety knowledge and behavior, medication self-management ability, medication self-efficacy and medication compliance. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
纳入标准包括年龄60周岁以上,在城市社区居住6个月以上,能听懂简单汉字交流,经三级综合医院确诊为高血压或糖尿病者。(a)高血压定义为收缩压≥140 mmHg和/或舒张压≥90 mmHg。(b)糖尿病的金标准是静脉血浆葡萄糖的测量,其定义为HbA1c≥6.5%(≥48 mmol/mol)或随机血浆葡萄糖≥200 mg/dl(≥11.1 mmol/l)或空腹血浆葡萄糖≥126 mg/dl(≥7.0 mmol/dl)或OGTT 2小时静脉血浆葡萄糖≥200 mg/dl(≥11.1 mmol/l)。 |
||||||||||||||||||||||
|
Inclusion criteria |
The inclusion criteria were as follows: aged 60 years or older, residing in urban communities for six months or longer, able to communicate and comprehend simple Chinese characters, and having a diagnosis of hypertension or diabetes confirmed by a Grade III general hospital. (a) hypertension defined as systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg. (b) diabetes of the gold standard is measurement of glucose in venous plasma, which defined as HbA1c ≥ 6.5 % (≥ 48 mmol/mol) or random plasma glucose ≥ 200 mg/dl (≥ 11.1 mmol/l) or fasting plasma glucose ≥ 126 mg/dl (≥ 7.0 mmol/dl) or OGTT 2?hour glucose in venous plasma ≥ 200 mg/dl (≥ 11.1 mmol/l). |
||||||||||||||||||||||
|
排除标准: |
排除标准包括听力障碍、语言障碍、严重认知障碍、精神疾病和其他严重或晚期疾病。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria encompassed hearing impairment, speech impairment, severe cognitive impairment, mental illness, and the presence of other severe or terminal illnesses. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-09-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-09-01 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
对招募的患者编号后,采用随机数字生成器网站(https://www.randomizer.org/)将他们分成两组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
To recruit patients after the number, the use of random number generator website (https://www.randomizer.org/) divided them into two groups. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本研究采用单盲法,参与者不知道分组情况。 |
|
Blinding: |
In this study, a single blind method was used, and the participants did not know the group status. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
我们将以论文的形式公布研究方案,对有需要原始数据的科研工作者,可以提供原始数据。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
we will publish the study protocol and will provide original data if required. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
由经过专门培训的资料收集员对数据进行测量和采集。采用excel 2016建立数据库,为保证数据录入的准确性,所有数据均双人录入;采用SPSS软件进行数据处理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data are measured and collected by the professional training nurses;the database is established using excel 2016, and then to ensure the accuracy of data, all data is entered by two researchers;SPSS will be used for data analysis. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |